CareDx Announces CEO Transition
01 Noviembre 2023 - 2:02PM
Business Wire
Board Establishes Office of the CEO, Conducts
Search for Successor
Raises 2023 Revenue Guidance
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on
the discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers – announced today that Dr. Reginald Seeto
will be stepping down from his position as Chief Executive Officer
and President and resigning as a Director of the Board effective
November 1, 2023, and will transition to the role of Senior Advisor
to the Chairperson.
CareDx will establish an Office of the CEO consisting of Board
Chairperson Michael Goldberg, Chief Financial Officer Abhishek Jain
and President of Patient and Testing Services Alexander Johnson.
The Board of Directors has initiated a search for a permanent CEO
and is considering both internal and external candidates.
“I look forward to working with Abhishek and Alex on an interim
basis to ensure we continue to execute our strategic plans while
the Board conducts a comprehensive search to identify a successor,”
said Mr. Goldberg. “We thank Dr. Seeto for his dedication to our
company and our mission during his tenure, and we wish him all the
best in his future endeavors.”
“I will be transitioning from my role as Chief Executive Officer
and President on November 1 and look forward to my next exciting
chapters in the healthcare world. I believe strongly in CareDx’s
patient-centric mission, and I am extremely proud of what we have
accomplished together,” said Dr. Seeto. “I wish the team well and
look forward to continuing to support the Company’s important work
in my new role as Senior Advisor to the Chairperson.”
CareDx delivered strong financial and operational performance in
the third quarter and has decided to raise its full year 2023
revenue guidance to be in the range of $274 to $278 million. CareDx
will provide more information during its third quarter earnings
call to be held on November 8, 2023, 1:30pm Pacific Time, 4:30pm
Eastern Time.
About CareDx – The Transplant CompanyTM
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the CEO transition,
CareDx’s search to identify a successor CEO and the company’s
updated revenue guidance for 2023. These forward-looking statements
are based upon information that is currently available to CareDx
and its current expectations, speak only as of the date hereof, and
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected, including risks
that CareDx does not identify a CEO successor on a timely basis;
the risk that revenue may decline or not meet internal
expectations; risks related to the Company’s ability to achieve
certain revenue targets and generate sufficient revenue from its
existing products; risks related to changes in governmental or
private insurers’ coverage and reimbursement levels for the
Company’s products; risks related to increased competition; general
economic and market factors; and other risks discussed in CareDx's
filings with the SEC, including the Annual Report on Form 10-K for
the fiscal year ended December 31, 2022 filed by CareDx with the
SEC on February 27, 2023, the quarterly report on Form 10-Q for the
quarter ended March 31, 2023 filed by CareDx with the SEC on May
10, 2023, the quarterly report on Form 10-Q for the quarter ended
June 30, 2023 filed by CareDx with the SEC on August 8, 2023, and
other reports that CareDx has filed with the SEC. Any of these may
cause CareDx's actual results, performance, or achievements to
differ materially and adversely from those anticipated or implied
by CareDx's forward-looking statements. CareDx expressly disclaims
any obligation, except as required by law, or undertaking to update
or revise any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101031914/en/
CareDx, Inc. Media Relations Anna Czene 818-731-2203
aczene@caredx.com
Investor Relations Greg Chodaczek investor@caredx.com
CareDx (NASDAQ:CDNA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
CareDx (NASDAQ:CDNA)
Gráfica de Acción Histórica
De May 2023 a May 2024